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Abstract
Background:  Several mechanisms operate during mitosis to ensure accurate chromosome
segregation. However, during tumour evolution these mechanisms go awry resulting in
chromosome instability. While several lines of evidence suggest that mutations in adenomatous
polyposis coli (APC) may promote chromosome instability, at least in colon cancer, the underlying
mechanisms remain unclear. Here, we turn our attention to GSK-3 – a protein kinase, which in
concert with APC, targets β-catenin for proteolysis – and ask whether GSK-3 is required for
accurate chromosome segregation.
Results: To probe the role of GSK-3 in mitosis, we inhibited GSK-3 kinase activity in cells using a
panel of small molecule inhibitors, including SB-415286, AR-A014418, 1-Azakenpaullone and
CHIR99021. Analysis of synchronised HeLa cells shows that GSK-3 inhibitors do not prevent G1/
S progression or cell division. They do, however, significantly delay mitotic exit, largely because
inhibitor-treated cells have difficulty aligning all their chromosomes. Although bipolar spindles form
and the majority of chromosomes biorient, one or more chromosomes often remain mono-
oriented near the spindle poles. Despite a prolonged mitotic delay, anaphase frequently initiates
without the last chromosome aligning, resulting in chromosome non-disjunction. To rule out the
possibility of "off-target" effects, we also used RNA interference to selectively repress GSK-3β.
Cells deficient for GSK-3β exhibit a similar chromosome alignment defect, with chromosomes
clustered near the spindle poles. GSK-3β repression also results in cells accumulating micronuclei,
a hallmark of chromosome missegregation.
Conclusion:  Thus, not only do our observations indicate a role for GSK-3 in accurate
chromosome segregation, but they also raise the possibility that, if used as therapeutic agents, GSK-
3 inhibitors may induce unwanted side effects by inducing chromosome instability.
Background
Genome stability requires that the replicated chromo-
somes are accurately segregated during mitosis [1]. Chro-
mosome segregation is mediated by a microtubule
spindle, to which chromosomes attach via their kineto-
chores, complex microtubule-binding structures which
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assemble at the centromeric heterochromatin [2-4]. Kine-
tochores not only attach chromosomes to the spindle,
they also perform two key functions which maintain chro-
mosome stability. Firstly, by undergoing rounds of micro-
tubule capture-and-release, kinetochores select
microtubule attachments which yield tension across the
centromere [5]. This in turn promotes chromosome biori-
entation, i.e. sister kinetochores attached to opposite spin-
dle poles. Secondly, by monitoring microtubule
occupancy and/or tension, kinetochores regulate the spin-
dle checkpoint, a surveillance mechanism which delays
anaphase until all the chromosomes are bioriented [6].
As a consequence of these mechanisms, most normal pro-
liferating human cells are diploid and karyotypically sta-
ble. By contrast, many tumour cells exhibit chromosome
instability and are therefore karyotypically unstable and
aneuploid [7]. Much effort has gone into defining the
genetic lesions responsible for the chromosome instabil-
ity and recently, adenomatous polyposis coli (APC) has
emerged as a candidate, at least in colon cancer [8,9]. APC
is best known for its role in the Wnt signalling pathway:
in the absence of Wnt signals, a destruction complex of
APC and axin recruits both β-catenin and GSK-3 [10,11].
Phosphorylation of β-catenin by GSK-3β then targets β-
catenin for proteolysis. In the presence of Wnt signals, β-
catenin phosphorylation is inhibited, resulting in the
upregulation of proliferative genes. This mechanism is
essential for tumour suppressor function in the colonic
epithelia: almost all colon cancers have either loss of func-
tion mutations in APC or activating mutations in β-cat-
enin [12]. However, APC is a large multi-domain protein
and its function is not restricted to the Wnt pathway.
Evidence is mounting that APC is somehow required for
the fidelity of chromosome segregation. APC is a microtu-
bule binding protein and has the ability to stabilise plus
ends [13]. In mitosis, APC localises to kinetochores in a
microtubule dependent manner [14,15], and tumour cells
with APC mutations have weaker kinetochore – microtu-
bule interactions [16,17]. Spindles assembled in Xenopus
egg extracts depleted of APC are abnormal [18]. APC also
localises to centrosomes [19-21], and in the Drosophila
germ line, APC is required for spindle positioning [22]. In
mice, APC mutation enhances genomic instability and
tumour formation in cells haploinsufficient for BubR1, a
spindle checkpoint kinase [23]. Murine embryonic stem
cells with APC mutations are frequently tetraploid
[14,15]. Ectopic expression of N-terminal APC mutants in
diploid, APC-proficient human cells compromises the
spindle checkpoint and enhances survival following pro-
longed mitotic arrest, leading to aneuploidy [21]. How-
ever, despite this body of evidence, the molecular
mechanisms linking APC and chromosome instability
remain unclear.
One possibility is that APC mutation compromises EB1, a
microtubule tip-tracking protein involved in microtubule
dynamics, spindle positioning, chromosome stability and
cytokinesis [24,25]. EB1 binds the C-terminus of APC
[26], so it is conceivable that the binding of N-terminal
APC mutants to partners, including full length APC,
excludes EB1 from complexes required for microtubule
processes [17]. Another possible mechanism lies with,
GSK-3. Like APC, the function of GSK-3 is not restricted to
the Wnt pathway, rather it has been implicated in a pleth-
ora of processes including glycogen metabolism and tau
phosphorylation [27-29], and more recently, regulating
kinesin-driven organelle movement [30] and Cyclin E
degradation [31]. Importantly, GSK-3 has been impli-
cated in regulating interphase microtubule dynamics [32].
Phosphorylated GSK-3 localises to spindle poles in mito-
sis [33]. In both budding and fission yeast, overexpression
of GSK-3 suppresses mutations in kinetochore proteins
and the centromeric DNA [34,35]. Interestingly, Bub1 and
BubR1, two related protein kinases which localise to kine-
tochores and are required for spindle checkpoint function
[36], phosphorylate APC in vitro [15]. While the signifi-
cance of this is unclear, phosphorylation is enhanced if
APC is already phosphorylated by GSK-3 [15]. In one
study, small molecule GSK-3 inhibitors were shown to
induce spindle defects and chromosome misalignment
[33]. However, whether these chromosomes eventually
aligned before anaphase onset is unclear. Indeed, we envi-
sion two possible scenarios; either the chromosomes
never align, yielding prolonged checkpoint arrest fol-
lowed by adaptation and mitotic exit without dividing,
yielding tetraploid cells [37]; or alternatively, the spindle
checkpoint "gives up" and the cells enter anaphase despite
unaligned chromosomes, thereby missegregating only
those chromosomes [38].
To distinguish between these possibilities and further
probe the role of GSK-3 in mitotic chromosome segrega-
tion, we characterised a panel of structurally diverse GSK-
3 inhibitors. We show that these inhibitors have profound
effects on cell cycle control, spindle morphology and
chromosome alignment. Strikingly, these inhibitors
increase the frequency with which cells missegregate their
chromosomes. In support of the notion that these pheno-
types are due to inhibition of GSK-3, rather than off target
effects, we use RNA interference to selectively repress GSK-
3β. This results in a chromosome alignment defect and
the formation of micronuclei, a hallmark of chromosome
missegregation.
Results
Characterisation of small molecule GSK-3 inhibitors
A number of small molecules have been identified which
inhibit GSK-3 in vitro [27]. To determine whether GSK-3
is required for accurate chromosome segregation, weBMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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obtained a panel of structurally diverse inhibitors (Fig. 1
and Table 1) and tested their ability to inhibit glycogen
synthase (GS) phosphorylation in cells [39,40]. As a neg-
ative control, we used DMSO, the solvent in which the
drugs were dissolved, and as a positive control we used
lithium chloride, a well established GSK-3 inhibitor
[41,42]. When HeLa cells were treated with GSK-3 inhibi-
tors for 24 hours, only SB-415286, AR-A014418, 1-Azak-
enpaullone, CHIR99021 and Inhibitor XI significantly
reduced GS phosphorylation (Fig. 2A). TDZD-8, Inhibitor
II and OTDZT had little effect (Fig. 2A), even when used
at relatively high concentrations (not shown).
Several GSK-3 inhibitors have been shown to inhibit
members of the CDK family, at least in vitro [27]. We
therefore asked whether cellular Cdk1 activity was inhib-
ited by the GSK-3 inhibitors used here. HeLa cells were
synchronised in mitosis with nocodazole then exposed to
GSK-3 inhibitors. In parallel, cells were exposed to a bone
fide Cdk1 inhibitor, RO-31-8220 [43]. To prevent mitotic
exit, the proteasome inhibitor MG132 was also added to
the cells. Cell lysates were then prepared and immunob-
lotted for phospho-nucleolin, a known Cdk1 substrate
(Fig. 2B). While RO-31-8220 clearly inhibited the phos-
phorylation of nucleolin, the GSK-3 inhibitors had no
apparent effect. Thus, at the concentrations where GSK-3
is clearly inhibited (Fig. 2A), there does not appear to be
any appreciable inhibition of Cdk1.
Next, we analysed spindle morphology in drug-treated
mitotic DLD-1 cells. In controls, or cells treated with com-
pounds which did not inhibit GS phosphorylation, nor-
mal metaphase spindles were readily apparent (Fig. 2C).
By contrast, cells treated with compounds which did
inhibit GS phosphorylation, frequently exhibited abnor-
mal chromosome configurations. Specifically, although
bipolar spindles formed and most chromosomes aligned
at the metaphase plate, some chromosomes were often
clustered near the spindle poles (Fig. 2C). For example, in
the presence of the highly specific GSK-3 inhibitor,
CHIR99021, ~49% of metaphases had one or more chro-
mosomes clustered near the spindle poles (Fig. 2D). Thus,
five structurally diverse small molecules which inhibit
GSK-3 activity in cells induced a chromosome alignment
defect.
GSK-3 inhibitors delay mitotic entry and exit
Although GSK-3 inhibitors have been used extensively to
study insulin action [44-47], very little is know about their
effects on the cell cycle. In light of the observation
described above, we therefore analysed the effect of GSK-
3 inhibitors on cell cycle progression. HeLa cells were syn-
chronised in early S-phase using a double thymidine
block then released into drug free media, or media supple-
mented with SB-415286 or nocodazole. Over the next 24
hours cells were harvested at regular intervals and ana-
lysed by flow cytometry to determine DNA content and
mitotic index. Control cells progressed through S-phase
then entered mitosis 9 hours after release (Fig. 3A, B). The
mitotic index peaked at ~20% 10 hours post-release then,
as division was completed, cells with 2N DNA contents
reappeared. 17 hours post-release, i.e. 5–6 hours after
returning to G1, these cells entered a second S-phase. Cells
Table 1: GSK-3 inhibitors used in this study
Compound Class Mechanism In vitro IC50 Conc. used in cells Ref.
SB-415286 Arylindole-maleimides ATP Competitor 78 nM 30 µM[ 4 4 ]
AR-A014418 Thiazole ATP Competitor 104 nM 20 µM[ 5 8 ]
1-Aza kenpaullone Benzazepinone ATP Competitor 18 nM 2.5 µM[ 5 7 ]
CHIR99021 Aminopyrimidine ATP Competitor 7 nM 10 µM[ 4 7 ]
Lithium Divalent ion Non competitive 2 mM 40 mM [41]
TDZD-8 Thiadiazolidinone Non competitive 2 µM1 0 – 6 0   µM[ 7 0 ]
Inhibitor II Pyridyloxadiazole - 390 nM 25–75 µM[ 7 1 ]
OTDZT Thiadiazolidinone Non competitive 10 µM 50–100 µM[ 7 0 ]
Inhibitor XI Azaindolylmaleimide ATP Competitor 32 nM 50 µM[ 7 2 ]
Small molecule inhibitors of GSK-3 Figure 1
Small molecule inhibitors of GSK-3. Chemical struc-
tures of SB-415286, 1-Azakenpaullone, AR-A014418 and 
CHIR99021BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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Identification of small molecules which inhibit GSK-3 in vivo Figure 2
Identification of small molecules which inhibit GSK-3 in vivo. HeLa and DLD-1 cells were incubated with small mole-
cule GSK-3 inhibitors for 24 hours then analysed by immunoblotting and immunofluorescence. (A) Immunoblot of HeLa cell 
extracts showing inhibition of glycogen synthase phosphorylation by a subset of GSK-3 inhibitors. (B) Immunoblot of HeLa cell 
extracts showing that GSK-3 inhibitors do not inhibit Cdk1 phosphorylation of nucleolin. (C) Images of mitotic DLD-1 cells 
showing examples of abnormal metaphase spindles following exposure to AR-A014418 and 1-Azakenpaullone. (D) Bar graph 
plotting the number of abnormal metaphases in cells treated with different small molecule GSK-3 inhibitors.
Table 2: Effect of SB-415286 inhibitors on mitotic timing
Compound Event Time (mins) s.e.m. Range N P
Untreated NEB-Metaphase 21.59 1.49 12–72 41 -
Metaphase-Anaphase 10.65 0.92 1.5–35.5 49 -
SB-415286 NEB-Metaphase 46.04 4.32 17.5–162 42 p < 0.01
Metaphase-Anaphase 11.32 1.2 1.5–55 57 p > 0.05
Values represent the mean time, in minutes, taken from nuclear envelope breakdown to metaphase and metaphase to anaphase in minutes. Also 
shown is showing the standard error of the mean, the range and the number of cells analysed. P values determined using a Kruskal-Wallis test.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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released into nocodazole completed S-phase but then,
consistent with hyper-activation of the spindle check-
point, arrested in mitosis maintaining 4N DNA contents.
Cells released into SB-415286 also progressed through the
first S-phase will normal kinetics (Fig. 3A) but the mitotic
index did not increase until 13 hours post-release, indicat-
ing a mitotic entry delay of ~3 hours (Fig. 3B). 17 hours
post-release, the mitotic index peaked at ~30%. After this,
the number of cells with 2N DNA contents started to
increase, indicating successful cell division. By 23 hours,
i.e. ~6 hours after they returned to G1, SB-415286-treated
cells entered a second S phase. Thus in HeLa cells, SB-
415286 has no apparent effect on G1/S progression and
neither does it prevent cell division. SB-415286 does how-
ever delay mitotic entry and mitotic exit.
GSK-3 inhibitors delay chromosome alignment
To determine why SB-415286 delayed mitotic progres-
sion, we analysed drug-treated DLD-1 cells by time-lapse
microscopy, using a GFP-tagged histone to visualise the
chromosomes [38]. Control cells typically aligned their
chromosomes within ~22 minutes (Table 2) then under-
went a normal anaphase (Fig. 4A). Note that untreated
cells never entered anaphase with unaligned chromo-
somes (Table 3). By contrast, chromosome alignment was
often delayed in SB-415286 treated cells and anaphase
was often initiated with unaligned chromosomes. For
example, Figure 4B shows two cells, marked a  and  b,
which, at T = 34 minutes still have unaligned chromo-
somes (one in a, and two in b, see arrow head and arrows
respectively). At T = 39 minutes, the last chromosome in
cell a aligns and anaphase initiates at T = 46. By T = 96.5
minutes, one of the laggards in cell b has congressed, but
GSK-3 inhibitors delay mitotic entry and exit Figure 3
GSK-3 inhibitors delay mitotic entry and exit. HeLa cells were synchronised at G1/S then released into drug-free 
medium or medium containing either SB-415286 or nocodazole. At the time points indicated the cells, were harvested and 
analysed by flow cytometry to determine DNA content and mitotic index. (A) DNA content histograms showing that SB-
415286 delays cell division. (B) Graph plotting the mitotic index, as determined by MPM-2 reactivity, showing that mitotic pro-
gression is delayed in SB-415286 treated cells.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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one remains unaligned (see asterisk). At T = 100.5, cell b
enters anaphase, without the last chromosome aligning.
To quantitate these effects, we measured the time taken
from prophase to metaphase, i.e. when the last chromo-
some aligned, and the time taken from metaphase to ana-
phase. While control cells took 21.6 ± 1.4 minutes to
reach metaphase, SB4-treated cells took, on average, 46.0
± 4.3 minutes (Fig. 4C, Table 2). Anaphase initiated ~11
minutes later in both control (10.7 ± 0.9 minutes) and SB-
415286-treated (11.3 ± 1.2 minutes) cells. Importantly
however, six out of thirty-two SB-415286 treated cells
entered anaphase with one or more unaligned chromo-
somes. This phenomenon was not restricted to SB-
415286. In a separate set of experiments, we measured the
time from nuclear envelope breakdown (NEB) to ana-
phase in the presence of SB-415286, AR-A014418, 1-Aza-
kenpaullone and CHIR99021. Like SB-415286, AR-
A014418 induced a prolonged mitotic delay (NEB to ana-
phase, 92.9 ± 4 minutes, Fig. 4D, Table 3). Following
chromosome alignment, anaphase initiated with normal
kinetics (not shown), confirming that the prolonged
mitosis was due to delayed chromosome alignment. 1-
Azakenpaullone and CHIR99021 induced modest but
never-the-less significant (p < 0.001) delays, (Fig. 4D,
Table 3). Importantly, a proportion of the cells exposed to
AR-A014418, 1-Azakenpaullone and CHIR99021 entered
anaphase with unaligned chromosomes (Table 3).
To see if such chromosome missegregation events would
lead to aneuploidy, diploid HCT116 cells were exposed
SB-415286 for 48 hours, metaphase spreads prepared
then chromosome number determined. At day 0, the
majority of untreated control cells had a near diploid
karyotype, with only 3% of the cells having more than 49
chromosomes (not shown). By contrast, 13.4% of cells
treated with SB-415286 had more than 49 chromosomes.
By day 5, the aneuploid population (>49 chromosomes)
in control cells was 5.6%, however in SB-415286 treated
cells, 26.3% were now aneuploid (not shown).
Thus, when exposed to GSK-3 inhibitors, chromosome
alignment is delayed and anaphase is often initiated in the
presence of unaligned chromosomes yielding aneuploid
cells.
GSK-3 inhibitors induce mono-orientations
To determine why complete chromosome alignment was
delayed in cells treated with GSK-3 inhibitors, we ana-
lysed K-fibres using high-resolution optical sectioning
microscopy. To visualise centromeres and kinetochores,
we stained cells with anti-centromere antibodies (ACA)
and anti-BubR1 antibodies respectively. In control cells,
chromosomes near the spindle equator were clearly biori-
ented: microtubules terminated at BubR1 foci which were
connected by ACA staining (Fig. 5A). In drug-treated cells,
chromosomes near the spindle equator also appeared to
be correctly bioriented (Fig. 5B). However, chromosomes
near the spindle poles were typically mono-oriented, with
one kinetochore attached to the nearest spindle pole and
the other unattached (Panels i in Fig. 5D, E). In some
cases, microtubules from the same pole could be seen
extending towards both kinetochores of an unaligned
chromosome, indicating a possible syntelic orientation
(Fig. 5C and panels ii in 5D, E). Thus, while GSK-3 inhib-
itors do not prevent kinetochore biorientation or chromo-
some congression, they do appear to inhibit the ability of
a cell to perfectly biorient all its chromosomes.
GSK-3 inhibitors alter spindle morphology
During the analysis described above (Figs 2B and 5), we
noticed that in drug-treated cells, spindle morphology
appeared abnormal in that there appeared to be increased
astral microtubules near the pole around which chromo-
somes clustered. In addition, spindle length appeared to
increase. Examples of both these phenotypes are shown in
Figure 6A. In panel i, the control cell shows a normal spin-
dle morphology, with the chromosomes aligned between
two robust crescent-shaped half spindles, and a small
number of astral microtubules projecting away from the
poles. In panel ii, the spindle seems abnormally long,
with the half spindles forming cones rather than crescents.
In panel iii, the pole on the right appears as a radial aster
Table 3: Effect of GSK-3 inhibitors on mitotic timing and chromosome non-disjunction
Compound Time (mins) s.e.m. Range N # P
- 25.37 0.35 16–42 189 0 -
SB4 69.56 3.44 26–214 99 15 p < 0.001
AR 92.88 10.02 24–268 41 3 p < 0.001
Ken 31.87 0.48 20–82 348 2 p < 0.001
CHIR 43.94 1.93 20–214 187 8 p < 0.001
Values represent the mean time, in minutes, taken from nuclear envelope breakdown to metaphase, Also shown is the standard error of the mean, 
the range, the number of cells analysed (N), the number of cells which enter anaphase with unaligned chromosomes (#). P values determined using 
a Kruskal-Wallis test.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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with equal numbers of microtubules pointing in all direc-
tions, rather than a crescent oriented towards the spindle
equator.
To quantitate these differences, we measured tubulin fluo-
rescence intensities from one end of the cell to the other
along the spindle axis [48]. When plotted as a function of
spindle position, the tubulin intensity typically gave two
peaks, corresponding to the spindle poles, and a trough,
GSK-3 inhibitors delay chromosome alignment Figure 4
GSK-3 inhibitors delay chromosome alignment. DLD-1 cells expressing a tagged GFP-Histone H2B were incubated in 
the presence or absence of small molecule GSK-3 inhibitors then analysed by time-lapse microscopy. (A) Control cell showing 
normal mitosis. (B) SB-415286-treated cells. While cell a completes mitosis normally, chromosome alignment in cell b is 
delayed (see arrows) and anaphase is initiated despite one unaligned chromosome (see *). (C) Box plot measuring time from 
prophase to metaphase and metaphase to anaphase for at least 42 cells. (D) Box plot measuring time taken from nuclear enve-
lope breakdown (NEB) to anaphase onset. Values taken from at least 41 cells.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
Page 8 of 17
(page number not for citation purposes)
GSK-3 inhibitors yield monopolar and syntelic attachments Figure 5
GSK-3 inhibitors yield monopolar and syntelic attachments. DLD-1 cells were incubated with GSK-3 inhibitors for 24 
hours then fixed and stained to detect DNA (red), tubulin (green), BubR1 (blue) and centromeres (ACA, red) as indicated. 
Images represent projections of deconvolved image stacks. (A) Control cell showing examples of bioriented chromosomes. 
(B) GSK-3 inhibitor treated cell showing that chromosomes near the metaphase plate are bioriented. (C-E) Inhibitor treated 
cells showing examples of either syntelic attachments (C, Dii, Eii) or monopolar attachments (Di, Ei). Bar is 5 µm when the 
entire spindle is shown or 1 µm in the enlargements. The cells in C-E were treated with 30 µM SB-415286.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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corresponding to the spindle midzone (Fig. 6B). In some
cells, the peaks were further apart in drug-treated cells
indicating an extended spindle length (Fig. 6B, top panel).
However, in other cases there appeared to be little differ-
ence (6B, bottom panel). When we measured the pole-to-
pole distance in control cells, the mean value was 8.4 ± 0.4
µm. The mean values derived from GSK-3 inhibitor-
treated cells were marginally higher, reaching 10.4 ± 0.6
µm in the presence of AR-A014418 (Fig. 6C). However
that these differences are not statistically significant (Table
4), possibly reflecting a small effect or our small sample
size.
Tubulin intensity along the spindle length was, however,
significantly different in drug-treated cells. In the exam-
ples shown in Figure 6B, the trough between the two
peaks – which corresponds to the spindle midzone – is
lower in both cases. Indeed, in control cells, the ratio of
tubulin intensity at the midzone compared to the maxi-
mum value in that cells was 0.39 ± 0.02 (Fig. 6D, Table 4).
By contrast, in drug-treated cells this value was reduced to
between 0.21 ± 0.01 in the presence of SB-415286, and
0.26 ± 0.02 in the presence of CHIR99021. Thus, GSK-3
inhibitors do appear to affect spindle morphology.
GSK-3 inhibitors reduce Bub1 levels at aligned 
chromosomes
The spindle checkpoint maintains chromosome stability
by delaying anaphase until all the chromosomes are cor-
rectly bioriented [49-51]. That cells treated with GSK-3
inhibitors delay mitosis in the presence of unaligned
chromosomes indicates that the spindle checkpoint is
largely intact (Fig. 3). Consistently, when exposed to the
spindle toxins taxol and nocodazole, SB-415286 treated
cells arrest in mitosis (data not shown). However, the
spindle checkpoint is capable of delaying anaphase in
response to a single unaligned chromosome [51,52].
Because drug-treated cells often enter anaphase with una-
ligned chromosomes (Fig. 3), it is possible that the GSK-3
inhibitors suppress the checkpoint signal below the
threshold required to detect a single unaligned chromo-
some. While many factors determine spindle checkpoint
signalling [53,54], kinetochore localisation of Bub1 and
BubR1 is required for full checkpoint function [37,55].
Therefore, we analysed the levels of kinetochore bound
Bub1 and BubR1 following drug exposure.
In control and drug-treated cells, Bub1 and BubR1 were
recruited to kinetochores in prophase and prometaphase
(not shown). In control cells, Bub1 and BubR1 persisted
at metaphase kinetochores, albeit at reduced levels (Fig.
7A, B). In drug-treated cells, Bub1 and BubR1 were clearly
present at the kinetochores of unaligned chromosomes.
Consistent with our previous observations suggesting that
Bub1 localisation is attachment-sensitive [36], Bub1
asymmetrically labelled the kinetochores of mono-ori-
ented chromosomes, with the unattached kinetochore
staining stronger (Fig. 7A, C). In addition, consistent with
our previous notion that BubR1 localisation is tension-
sensitive [36], BubR1 staining was more symmetrical at
the kinetochores of mono-oriented chromosomes (Fig.
7B, C). Furthermore, pixel intensity-measurements
revealed that the levels of Bub1 and BubR1 at these una-
ligned chromosomes were no different from unaligned
kinetochores in control cells (data not shown). Thus,
prior to chromosome alignment, the behaviour of Bub1
Table 4: Effect of GSK-3 inhibitors on spindle morphology
Parameter Control SB-415286 AR-A014418 1-Aza kenpaullone CHIR99021
Pole-Pole Distance (µm) 8.39 ± 0.45 9.45 ± 0.37 10.36 ± 0.57 9.06 ± 0.39 8.18 ± 0.33
(22)* (20) (19) (20) (18)
- p > 0.05§ p < 0.05 p > 0.05 p > 0.05
Tubulin Intensity (midzone/cell max) 0.39 ± 0.02 0.21 ± 0.01 0.25 ± 0.01 0.24 ± 0.01 0.26 ± 0.02
(15)* (20) (19) (20) (18)
- p < 0.001 p < 0.01 p < 0.001 p < 0.05
Interkinetochore Distance (µm) 0.91 ± 0.04 1.04 ± 0.03 1.05 ± 0.04 0.93 ± 0.02 0.92 ± 0.02
(40, 4) (33, 4) (20, 3) (52, 4) (41, 4)
- p < 0.05 p > 0.05 p > 0.05 p > 0.05
Bub1 Intensity (Bub1:ACA) 100.00 ± 3.30 42.59 ± 0.85 24.24 ± 0.40 46.20 ± 0.98 68.50 ± 0.79
(76, 4)‡ (64, 4) (116, 3) (81, 4) (124, 5)
- p < 0.05 p < 0.001 p < 0.001 p > 0.05
BubR1 Intensity (BubR1:ACA) 100.00 ± 0.40 63.67 ± 0.30 31.49 ± 1.24 89.27 ± 0.75 84.08 ± 0.49
(121, 7)‡ (115, 6) (133, 4) (176, 6) (127, 5)
- p < 0.001 p < 0.001 p < 0.001 p < 0.001
Quantitation of spindle length (pole to pole distance), inter-kinetochore distance and kinetochore localisation of Bub1 and BubR1 in DLD-1 cells 
treated with GSK-3 inhibitors.
* Values in parentheses (Number of cells)
‡ Values in parentheses (Number of kinetochores, Number of cells)
§ Kruskal-Wallis Test (Nonparametric ANOVA), Dunn's Multiple Comparisons Test.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
Page 10 of 17
(page number not for citation purposes)
and BubR1 appear largely normal in the presence of the
GSK-3 inhibitors.
The abundance of Bub1 and BubR1 at aligned chromo-
somes was however significantly reduced (Fig. 7A, B and
Table 4). Pixel intensity-measurements showed that SB-
415286, AR-A014418, 1-Azakenpaullone and
CHIR99021 all reduced kinetochore bound Bub1, down
to 25% in the case of AR-A014418 (Fig. 7E and Table 4).
Kinetochore bound BubR1 was also reduced by all four
drugs, most notably by SB-415286 and AR-A014418 (Fig.
7F and Table 4). One explanation for these observations
is that the bioriented kinetochores had higher microtu-
bule occupancy and/or were under more tension. To test
this, we measured the inter-kinetochore distances of
aligned chromosomes. In control cells, the mean inter-
kinetochore distance was 0.91 ± 0.04 µm. In SB-415286-
and AR-A014418-treated cells, this value increased to
~1.05 µm, a statistically significant difference (Fig 7D and
Table 4). Although 1-Azakenpaullone and CHIR99021
had little effect, note that there is a correlation between
inter-kinetochore distance and BubR1 levels. While SB-
415286 and AR-A014418 increased inter-kinetochore dis-
tance and reduced BubR1, 1-Azakenpaullone and
CHIR99021 had only modest effects on BubR1 binding
and inter-kinetochore distance (Table 4). Significantly,
SB-415286 and AR-A014418 also had more penetrant
effects on chromosome alignment (Figs 2C, 3D) and pole-
to-pole distance (Fig. 6C and Table 4).
GSK-3β RNAi induces mitotic defects
Our observations demonstrate that several different GSK-
3 inhibitors effect spindle morphology and chromosome
alignment, and elevate the chromosomes missegregation
rate. Because we used a panel of structurally diverse com-
pounds (Fig. 1), the simplest explanation is that the effects
are due to inhibition of GSK-3. However, to rule out the
possibility that the phenotypes observed may be due to
off-target effects, we asked whether repression of GSK-3β
by RNA interference yielded similar effects. We focussed
on GSK-3β because this isoform localises to the mitotic
spindle [33]. DLD-1 cells were transfected with siRNA
duplexes designed to repress GSK-3β then immunoblot-
ted with an antibody which recognises both GSK-3α and
GSK-3β. Importantly, we observed a significant and selec-
tive reduction in GSK-3β levels (Fig. 8A). In the GSK-3β
RNAi population, we frequently observed cells with
micronuclei in the GSK-3β RNAi population (Fig. 8B), an
indicator of chromosome missegregation [56]. Quantita-
tion revealed that GSK-3β RNAi increased the number of
cells with micronuclei by a factor of two 48-hours post
transfection, and by almost 4-fold at 72 hours (Fig. 8C).
Furthermore, we frequently observed metaphase spindles
with multiple unaligned chromosomes (Fig. 8D). Quanti-
tation showed a greater than 3-fold increase in such fig-
ures 72 hours after transfection (Fig. 8E). The spindle also
appeared abnormal following GSK-3β RNAi, with an
increase in astral microtubules (not shown) and an
increase in spindle length; the mean pole-to-pole distance
following repression of GSK-3β was 8.3 ± 0.4 µm com-
pared to 7.7 ± 0.3 µm in control cells. Tubulin intensity at
the spindle midzone was also significantly reduced (p <
0.05) following GSK-3β RNAi (Fig. 8F). BubR1 levels at
metaphase kinetochores was significantly reduced; the
mean BubR1/ACA ratio was 4.37 ± 0.94 in controls com-
pared to 2.76 ± 0.24 in GSK-3β-deficient cells (p < 0.05).
Inter-kinetochore distance was also significantly increased
from 1.02 ± 0.03 µm in controls to 1.15 ± 0.04 µm follow-
ing repression of GSK-3β (p < 0.05). Thus, as observed
with the small molecule GSK-3 inhibitors, RNAi-medi-
ated repression of GSK-3β affects spindle morphology,
inhibits chromosome alignment and the fidelity of chro-
mosome segregation.
Discussion
Small molecule GSK-3 inhibitors inhibit chromosome 
alignment
Here, we use small molecule inhibitors to probe GSK-3
function in cell cycle progression and mitotic chromo-
some segregation. Several inhibitors, including SB-
415286, AR-A014418, 1-Azakenpaullone and
CHIR99021, all significantly reduced phosphorylation of
glycogen synthase in cells, indicating efficient cellular
inhibition of GSK-3. Importantly, these four compounds
inhibit chromosome alignment. Several other com-
pounds, which reportedly inhibit GSK-3 in vitro, had little
effect on glycogen synthase phosphorylation and had no
effect on chromosome alignment. Why these latter inhib-
itors did not inhibit GSK-3 activity in cells is unclear but
could be due to trivial reasons such as limited permeabil-
ity. While the mode of action of these latter inhibitors is
non-ATP competitive, the inhibitors which did inhibit
GSK-3 activity in cells were all ATP competitors. This
raises the possibility that their cellular effects may be due
to inhibition of other protein kinases. However, all four
inhibitors are relatively specific for GSK-3 inhibitors, at
least in vitro [44,47,57,58]. Furthermore, they are all from
different chemical classes and therefore likely to have dif-
ferent spectrums of "off-target" effects. Thus, the simplest
explanation is that the chromosome alignment defect is
due to inhibition of GSK-3. Indeed, the similarities
between the GSK-3β RNAi phenotype and the inhibitor-
induced phenotypes lends further weight to this notion.
However, it will be important to test this hypothesis fur-
ther in future studies, in particular the identification and
characterisation of drug-resistant GSK3-β mutants will
provide a powerful approach to dissecting the role of GSK-
3 in cell cycle processes. In addition, analysing the effects
these inhibitors have on GSK-3 null cells will help deline-
ate off-target effects.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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Regulation of GSK-3 at the spindle pole
The observation that phospho-GSK-3α/β (Ser21/9) local-
ises to spindle poles in mitosis [33], raises the possibility
that GSK-3 is somehow involved in regulating microtu-
bule dynamics and/or spindle pole function. Indeed,
Wakefield et al showed that cells treated with two GSK-3
inhibitors, SB-2 and SB-4 affected spindle assembly and
inhibited chromosome alignment. Here, we have
extended the observations of Wakefield et al by (a) using
a panel of diverse GSK-3 inhibitors, (b) demonstrating
that mitotic phenotypes correlate with GSK-3 inhibition
and (c) further characterising the mitotic defects. In addi-
tion, we show that cells treated with GSK-3 inhibitors
enter anaphase with unaligned chromosomes. Consistent
with Wakefield et al, our observations indicate that spin-
dle morphology was frequently abnormal in cells treated
with GSK inhibitors, with elevated numbers of astral
microtubules. Interestingly, in vitro, GSK-3 phosphor-
ylates another centrosomal kinase, Aurora A, on serines
290/291[59]. This in turn results in Aurora A auto-phos-
phorylation on serine 349. When S290/291 and S349
were mutated to phospho-mimicing aspartates, Aurora A
was less active towards CPEB, a substrate that becomes
phosphorylated in Xenopus oocytes following progester-
one stimulation [59]. This phosphorylation event results
in the translation of mos and Cyclin B mRNAs, which in
GSK-3 inhibitors weaken the spindle midzone Figure 6
GSK-3 inhibitors weaken the spindle midzone. DLD-1 cells were incubated for 24 hours with GSK-3 inhibitors then 
fixed and stained to detect the microtubules and the chromosomes. (A) Projections of deconvolved image stacks showing rep-
resentative mitotic spindles. Scale bar: 5 µm. (B) Graphs plotting tubulin intensity along the spindle axis. (C) Bar graphs plotting 
pole-pole distance. Values represent the mean and s.e.m. derived from at least 18 cells. (D) Bar graphs quantifying the tubulin 
intensity at the spindle midzone. Values represent the mean and s.e.m. derived from at least 15 cells. The cells in parts A-B 
were treated with either 2.5 µM 1-Azakenpaullone or 30 µM SB-415286BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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GSK-3 inhibitors increase inter-kinetochore distance Figure 7
GSK-3 inhibitors increase inter-kinetochore distance. Drug-treated DLD-1 cells were fixed and stained to detect cen-
tromeres (ACA, red), kinetochores (Bub1 or BubR1, green), microtubules (green or blue) and the chromosomes (red) as indi-
cated. (A, B) Projections of deconvolved image stacks showing reduced levels of Bub1 and BubR1 is at metaphase-
kinetochores is reduced in GSK-3 inhibitor treated cells. Scale bars: 5 µm. (C) Projections of deconvolved image stacks show-
ing the asymmetric labelling of Bub1 on the kinetochore of mono-orientated chromosomes. (D) Bar graph quantifying inter-
kinetochore distance at metaphase chromosomes. Values represent the mean and s.e.m. derived from at least 20 kinetochores 
in at least 3 cells. (E, F) Bar graphs quantifying the levels of Bub1 and BubR1 at aligned chromosomes. Values represent the 
mean and s.e.m. derived from at least 64 kinetochores in at least 3 cells. The cells shown in (A) were treated with 30 µM SB-
415286 and in (B) with 10 µM CHIR99021.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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GSK-3β RNAi inhibits chromosome alignment Figure 8
GSK-3β RNAi inhibits chromosome alignment. DLD-1 cells were transfected with siRNA duplexes designed to repress 
GSK-3β then analysed by immunoblot and immunofluorescence. (A) Immunoblot showing repression of GSK-3β. (B) Images of 
interphase cells showing micronuclei following repression of GSK3-β. (C) Scatter plot quantitating cells with micronuclei. The 
data is derived from four independent experiments, with each symbol representing an individual coverslip from which a mini-
mum of 1,000 cells was counted. (D) Images of mitotic cells showing chromosome alignment defects in GSK-3β deficient cells. 
Bar = 5 µm. (E) Box plot quantitating abnormal metaphases in control (black bar) and GSK-3β RNAi (white bar) populations, 
48 and 72 hours after transfection. The data is derived from three independent experiments. (F) Bar graphs quantifying the 
tubulin intensity at the spindle midzone. Values represent the mean and s.e.m. derived from at least 5 cells.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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turn drives cell cycle progression. Conversely, an Aurora A
harbouring non-phosphorylatable alanines at 290/291
and 349 was constitutively active towards CPEB. Thus,
GSK-3 appears to negatively regulate Aurora A, at least in
Xenpous  oocyte maturation. Whether GSK-3 phosphor-
ylates Aurora A in somatic cells remains to be seen, but
evidence from several systems indicate that Aurora A is
required for spindle assembly [60-62], and recently, we
have shown that Aurora A kinase activity is required for
spindle assembly in human cells [63]. Because GSK-3 is
inactive when phosphorylated on serine 21/9, it is possi-
ble that downregulation of GSK-3 at the spindle poles
allows localised Aurora A activation, which in turn mod-
ulates microtubule function thereby facilitating spindle
assembly. Whether GSK-3 is active away from the centro-
some in mitosis remains to be seen, but it is conceivable
that drug-mediated inhibition of GSK-3 could result in
activation of Aurora A elsewhere in the cell, not just at the
spindle pole. This in turn may stabilise microtubules
resulting in the excessive asters observed in drug-treated
cells.
GSK-3, kinetochore – microtubule interactions and the 
spindle checkpoint
Cells treated with GSK-3 inhibitors align most of their
chromosomes but have difficulty aligning them all and
frequently enter anaphase with unaligned chromosomes.
While the spindle defects may be sufficient to explain the
chromosome misalignment, it is also possible that GSK-3
inhibition affects kinetochore behaviour. Support for this
notion comes from the observation that the spindle
checkpoint – which requires kinetochore function – is
attenuated following GSK-3 inhibition. Clearly the spin-
dle checkpoint is largely intact following GSK-3 inhibi-
tion: drug-treated cells delay anaphase onset in the
presence of unaligned chromosomes (Fig. 4) and arrest
when the spindle is destroyed with nocodazole (data not
shown) However, drug-treated cells do enter anaphase
with unaligned chromosomes, something which control
cells never do. Furthermore, when HeLa cells were
released from a G1/S block into SB-415286 plus nocoda-
zole, the population mounted an attenuated checkpoint
response, exhibiting a maximal mitotic index of ~40%
(data not shown) compared to ~80% in controls (Fig. 3).
Why the spindle checkpoint in GSK-3-inhibitor treated
cells is attenuated remains to be seen: we did not observe
any significant changes with respect to the levels of Bub1
and BubR1 at unaligned kinetochores (not shown). Inter-
estingly however, levels of Bub1 and BubR1 were
decreased at kinetochores of aligned chromosomes (Fig.
6). Because levels of kinetochore-bound Bub1 and BubR1
are indicators of microtubule occupancy and tension
respectively [36], this suggests that GSK-3-inhibition actu-
ally promotes kinetochore – microtubule interactions.
Consistently, inter-kinetochore distances increase in the
presence of SB-415286 and AR-A014414. One possibility
is that GSK-3-inhibition affects the spindle checkpoint via
APC. Bub1 and BubR1 phosphorylate APC in vitro, an
event which is enhanced if APC is already phosphorylated
by GSK-3 [15]. Thus, following GSK-3 inhibition, phos-
phorylation of APC by Bub1 and BubR1 maybe attenu-
ated.
Recently cells depleted of APC or expressing dominant
negative mutants have been shown to have weakened col-
lapsed spindles, defective kinetochore attachments, an
increase in levels of kinetochore bound Bub1 and BubR1
and a decrease in tension across the kinetochore [16-
18,21,64]. However, there appears to be no anaphase
delay even though these cells go on and missegregate their
chromosomes [65]. In contrast when GSK-3 is inhibited
we observe an increase in spindle length and astral micro-
tubules, a decrease in the level of kinetochore bound
Bub1 and BubR1, an increase in the interkinetochore dis-
tance and a delay in chromosome alignment. This raises
the possibility that GSK-3 negatively regulates APC's
mitotic functions such that inhibiting GSK-3 activates
APC, thereby yielding the opposite phenotype to APC
depletion. Indeed inhibition of GSK-3 increases APC-
microtubule interactions [13] which may help stabilise
kinetochore-microtubule interactions.
Conclusion
GSK-3 and CIN
Our observations show that, at least in cultured cells, GSK-
3 inhibitors induce chromosome non-disjunction, a phe-
notype that we also observed following RNAi-mediated
repression of GSK-3β. Although GSK-3 inhibition affects
spindle morphology, the chromosome alignment defect is
the major contributing factor to non-disjunction. Is it pos-
sible that GSK-3 dysfunction causes chromosome insta-
bility in tumours? We feel that this is unlikely. Firstly,
GSK-3 is rarely mutated in cancer [66]. Secondly, mouse
knockouts are embryonic lethal [67]. Thus, in light of its
essential and multi-faceted functions, GSK-3 dysfunction
is likely to lead to cell death rather than provide a growth
advantage. However, GSK-3 inhibitors are currently being
investigated as potential therapeutics for a variety of
chronic diseases such as diabetes and neurodegenerative
disorders. Our observations suggest that GSK-3 inhibitors
may have an unexpected consequence in these settings,
namely the induction of chromosome instability, which
may in turn promote tumourigenesis. Efforts to determine
whether GSK-3 inhibitors induce chromosome instability
in mouse models and patients seem to us to be impera-
tive.BMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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Methods
Cell culture and GSK-3 inhibitors
HeLa, HCT116, DLD-1 and DLD-1 cells stably expressing
GFP-Histone H2B were all as described previously [38].
Cell culture conditions were as described [36]. Nocoda-
zole (Sigma, 10 mg/ml in DMSO) was used at a final con-
centration of 0.2 µg/ml. The proteasome inhibitor
MG132 (Calbiochem, 20 mM in DMSO) was used at a
final concentration of 20 µM. RO-31-8220 (Calbiochem,
10 mM in DMSO) was used at a final concentration of 10
µM. SB-415286 (Tocris; 25 mM), TDZD-8 (Calbiochem;
20 mM), Inhibitor II (Calbiochem, 25 mM), OTDZT (Cal-
biochem; 31.8 mM), Inhibitor XI (Calbiochem; 25 mM),
1-Azakenpaullone (Calbiochem; 25 mM), AR-A014418
(Calbiochem, 25 mM), and CHIR99021 (kind gift from
Philip Cohen; 10 mM) were dissolved in DMSO at the
concentrations indicated, stored at -20°C in individual
aliquots to avoid freeze thaw cycles, then freshly diluted
in media. DMSO was added to control cultures to account
for the solvent. Lithium Chloride (BDH) was dissolved in
water at concentration of 1 M, filter sterilised and used at
a final concentration of 40 mM.
Antibody Techniques
Immunoblotting was done as described previously
[21,36] using the following antibodies: rabbit anti-phos-
pho-glycogen synthase (Cell Signalling Tech, 1:1,000);
mouse anti-glycogen synthase kinase 3 (4G-1E, Upstate,
1:500); mouse anti-phospho-nucleolin (TG3, kindly pro-
vided by Peter Davies, 1:25); sheep anti-Bub3 (SB3.2,
1:1000). Immunofluorescence was done as described [21]
using the following antibodies: TAT-1, mouse anti-tubu-
lin (1:100, ref. [68]); SBR1.1, sheep anti-BubR1 (1:1,000,
ref [36]); SB1.3, sheep anti-Bub1 (1:1,000, ref [36]); ACA,
human anti-centromere (kindly provided by Bill Earn-
shaw, 1:800). To analyse kinetochore – microtubule inter-
actions and spindle morphology, cells were permeabilised
for 90 seconds in a microtubule stabilising buffer (100
mM PIPES pH 6.8, 1 Mm MgCl, 0.1 Mm CaCl2, 0.1% Tri-
ton X-100), fixed for 10 minutes in 4% formaldehyde,
then blocked and incubated with the appropriate primary
antibodies as described above. Following washes with
PBST, cells were stained for 30 minutes at room tempera-
ture with the appropriate Cy2-, Cy3- or Cy5- conjugated
secondary antibodies (Jackson Immuno-Research Labora-
tories), all diluted 1:500. Following washes, cells were
stained with Hoechst 33358 at 1 µg/ml in PBST then
mounted in 90% glycerol, 20 mM Tris-HCl pH 8.0.
Deconvolution microscopy and pixel intensity quantita-
tion was performed using a wide field optical sectioning
microscope (Deltavision, Applied Precision) as described
previously [36]. Briefly, for each cell, a Z-series of images
at 0.2 µm intervals was captured at each wavelength and
then processed using constrained iterative deconvolution.
Deconvolved image stacks were projected and fluores-
cence signal intensities quantified using SoftWoRx
(Applied Precision). To quantify the kinetochore bound
protein, the average pixel intensities from at least 64 kine-
tochores from three or more cells was measured, back-
ground readings were subtracted and the values were then
normalised against the ACA signal to account for any var-
iations in staining or image acquisition. SoftWoRx was
used to measure inter-kinetochore distance using Bub1
foci as indicated to determine kinetochore position.
Tubulin intensity was determined as described previously
[21,48]. Statistical analysis was performed using
InStat®v3.0 (GraphPad Software Inc).
Cell biology
DNA content and mitotic index measurements and syn-
chronisation of TA-HeLa cells at G1/S using double thy-
midine block were done as described previously [37], but
using an FSE-conjugated MPM-2 antibody (Upstate Bio-
tech). At least 10,000 cells were then analysed on a FACS-
CAN (Becton Dickson). For time-lapse analysis, DLD-1
cells expressing the GFP-Histone fusion protein were cul-
tured on either individual 35 mm glass bottomed Petri
dishes or 35 mm glass bottomed 6-well plates (MatTek
Co). Microscopy was performed on a manual Axiovert
200 (Zeiss), equipped with a PZ-2000 automated stage
(Applied Scientific Instrumentation) and an environmen-
tal control chamber (Solent Scientific), which maintained
the cells at 37°C in a humidified stream of 5% CO2, 95%
air. Shutters, filter wheels and point visiting were driven
by Metamorph software (Universal Imaging). Images
were taken using a CoolSNAP HQ camera (Photometrics),
while individual TIFF files were imported into Photoshop
(Adobe) for printing or QuickTime (Apple) for movies.
Nuclear envelope breakdown (NEB) was judged as the
point when the prophase chromatin lost a smooth, linear
periphery and the time of anaphase onset to be the first
frame where coordinated pole wards movement was
observed. Mitotic timing data is presented as box-and-
whisker plots generated with Prism 4 (GraphPad), where
the boxes show the median and interquartile range, while
the whiskers show the entire range.
RNAi
siRNA duplexes (SMARTpool, Dharmacon Research)
designed to repress GSK-3β or non-specific control pool
duplexes or siRNA duplexes designed to target lamin
B1were transfected into DLD-1 cells using Oligo-
fectAMINE™ (Invitrogen) as describe [69]. In brief, 4 × 104
cells were seeded in 24-well plates 24 hours prior to trans-
fection in growth media without antibiotics. siRNA
duplexes were mixed with OligofectAMINE™ in OptiMEM
media without antibiotics and incubated for 20 minutes.
siRNA/lipid complexes were then added to cells for 6
hours followed by addition of complete media containing
20% foetal calf serum. 24 hours later the cells wereBMC Cell Biology 2007, 8:34 http://www.biomedcentral.com/1471-2121/8/34
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replated onto coverslips or 6 well plates then analysed 24
hours later.
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